Hunter D. Reavis

493 total citations
14 papers, 264 citations indexed

About

Hunter D. Reavis is a scholar working on Molecular Biology, Reproductive Medicine and Oncology. According to data from OpenAlex, Hunter D. Reavis has authored 14 papers receiving a total of 264 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Reproductive Medicine and 3 papers in Oncology. Recurrent topics in Hunter D. Reavis's work include DNA Repair Mechanisms (4 papers), Ovarian cancer diagnosis and treatment (4 papers) and Cancer, Stress, Anesthesia, and Immune Response (3 papers). Hunter D. Reavis is often cited by papers focused on DNA Repair Mechanisms (4 papers), Ovarian cancer diagnosis and treatment (4 papers) and Cancer, Stress, Anesthesia, and Immune Response (3 papers). Hunter D. Reavis collaborates with scholars based in United States, Germany and Israel. Hunter D. Reavis's co-authors include Ronny Drapkin, H. Isaac Chen, Alan D. D’Andrea, Jean‐Bernard Lazaro, Larissa A. Sambel, Geoffrey I. Shapiro, Joyce F. Liu, Ursula A. Matulonis, Sangeetha Palakurthi and Panagiotis A. Konstantinopoulos and has published in prestigious journals such as Analytical Chemistry, Cancer Research and Clinical Cancer Research.

In The Last Decade

Hunter D. Reavis

13 papers receiving 262 citations

Peers

Countries citing papers authored by Hunter D. Reavis

Since Specialization

Citations

This map shows the geographic impact of Hunter D. Reavis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hunter D. Reavis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hunter D. Reavis more than expected).

Fields of papers citing papers by Hunter D. Reavis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hunter D. Reavis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hunter D. Reavis. The network helps show where Hunter D. Reavis may publish in the future.

Co-authorship network of co-authors of Hunter D. Reavis

This figure shows the co-authorship network connecting the top 25 collaborators of Hunter D. Reavis. A scholar is included among the top collaborators of Hunter D. Reavis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hunter D. Reavis. Hunter D. Reavis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Deuterium magnetic resonance imaging of tumors using low-dose systemic deuterated water labeling 2026 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), Hunter D. Reavis, Steven G. Turowski, Michael E. Feigin, (unknown), Joseph A. Spernyak, Nataliya P. Buxbaum	0
2	Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells 2024 ·JCI Insight ·Hunter D. Reavis, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Marilyn A. Mitchell, Dara S. Berger, (unknown), (unknown), Monica Mainigi, Marcin Iwanicki, Dave S.�B. Hoon, Laura M. Sanchez, Ronny Drapkin	11
3	L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary 2022 ·Communications Biology ·Kai Doberstein, (unknown), Hunter D. Reavis, Jagmohan Hooda, Yi Feng, Paul Kroeger, (unknown), Gordon B. Mills, Kyle M. Devins, Lauren E. Schwartz, Marcin Iwanicki, Mina Fogel, Peter Altevogt, Ronny Drapkin	11
4	Norepinephrine promotes anoikis resistance in fallopian tube secretory cells through beta adrenergic receptor signaling (247) 2022 ·Gynecologic Oncology ·Stefan Gysler, Hunter D. Reavis, (unknown), (unknown), Ronny Drapkin	1
5	Abstract 4071: Utilizing colforsin as a novel therapeutic for high grade serous ovarian cancer treatment 2022 ·Cancer Research ·(unknown), Hunter D. Reavis, Marilyn A. Mitchell, Ronny Drapkin	1
6	MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity 2021 ·Cell Reports ·Timothy B. Branigan, David Kozono, Amy E. Schade, Peter Deraska, (unknown), Larissa A. Sambel, Hunter D. Reavis, Geoffrey I. Shapiro, Alan D. D’Andrea, James A. DeCaprio	27
7	The tubal epigenome – An emerging target for ovarian cancer 2020 ·Pharmacology & Therapeutics ·Hunter D. Reavis, Ronny Drapkin	13
8	Tumor Innervation: Cancer Has Some Nerve 2020 ·Trends in cancer ·Hunter D. Reavis, H. Isaac Chen, Ronny Drapkin	70
9	The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition 2019 ·Clinical Cancer Research ·Kalindi Parmar, Bose Kochupurakkal, Jean‐Bernard Lazaro, Zhigang C. Wang, Sangeetha Palakurthi, Paul T. Kirschmeier, Chunyu Yang, Larissa A. Sambel, Anniina Färkkilä, Elizaveta Reznichenko, Hunter D. Reavis, Connor E. Dunn, Lee Zou, T. Khanh, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Joyce F. Liu, Alan D. D’Andrea, Geoffrey I. Shapiro	103
10	H2Bub1: Guardian of Chromatin Accessibility in Ovarian Cancer 2019 ·Oncoscience ·Hunter D. Reavis, Ronny Drapkin	1
11	NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair 2018 ·Cell Death Discovery ·Peter Deraska, Colin O’Leary, Hunter D. Reavis, (unknown), (unknown), Jean‐Bernard Lazaro, Christopher J. Sweeney, Alan D. D’Andrea, David Kozono	17
12	Abstract 4189: Homologous recombination pathway-based biomarkers for treatment of non-small cell lung cancer with PARP inhibitors 2017 ·Cancer Research ·Peter Deraska, Hunter D. Reavis, (unknown), Alan D. D’Andrea, David Kozono	1
13	Abstract 2796: Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity 2017 ·Cancer Research ·Bose Kochupurakkal, Kalindi Parmar, Jean‐Bernard Lazaro, Christine Unitt, Qing Zeng, Hunter D. Reavis, (unknown), Shan Zhou, Joyce F. Liu, Sangeetha Palakurthi, Kyle C. Strickland, Brooke E. Howitt, Panagiotis A. Konstantinopoulos, Paul T. Kirschmeier, Joseph Geradts, Ronny Drapkin, Ursula A. Matulonis, Alan D. D’Andrea, Geoffrey I. Shapiro	4
14	Quantitative, Point-of-Care Immunoassay Platform to Guide and Monitor Sickle Cell Disease Therapy 2016 ·Analytical Chemistry ·Xiaoxi Yang, Hunter D. Reavis, (unknown), Jason Kim	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact